Latamoxef: Difference between revisions
m Protected "Latamoxef": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
m Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +) |
||
| Line 25: | Line 25: | ||
}} | }} | ||
{{SI}} | {{SI}} | ||
'''Latamoxef''' (or '''moxalactam''') is an oxacephem [[antibiotic]] usually grouped with the [[cephalosporin]]s. In oxacephems such as latamoxef, the [[sulfur]] atom of the cephalosporin core is replaced with an [[oxygen]] atom. | '''Latamoxef''' (or '''moxalactam''') is an oxacephem [[antibiotic]] usually grouped with the [[cephalosporin]]s. In oxacephems such as latamoxef, the [[sulfur]] atom of the cephalosporin core is replaced with an [[oxygen]] atom. | ||
| Line 37: | Line 37: | ||
[[Category:Cephalosporin antibiotics]] | [[Category:Cephalosporin antibiotics]] | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WS}} | {{WS}} | ||
Revision as of 16:47, 9 August 2012
| File:Latamoxef.svg | |
| Clinical data | |
|---|---|
| Routes of administration | Intramuscular, intravenous |
| ATC code | |
| Pharmacokinetic data | |
| Protein binding | 35 to 50% |
| Metabolism | Nil |
| Elimination half-life | 2 hours |
| Excretion | Mostly renal, unchanged; also biliary |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C20H20N6O9S |
| Molar mass | 520.474 g/mol |
|
WikiDoc Resources for Latamoxef |
|
Articles |
|---|
|
Most recent articles on Latamoxef |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Latamoxef at Clinical Trials.gov Clinical Trials on Latamoxef at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Latamoxef
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Latamoxef Discussion groups on Latamoxef Directions to Hospitals Treating Latamoxef Risk calculators and risk factors for Latamoxef
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Latamoxef |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Latamoxef (or moxalactam) is an oxacephem antibiotic usually grouped with the cephalosporins. In oxacephems such as latamoxef, the sulfur atom of the cephalosporin core is replaced with an oxygen atom.
Latamoxef has been associated with prolonged bleeding time, and several cases of coagulopathy, some fatal, were reported during the 1980s.[1][2] Latamoxef is no longer available in the United States.
References
- ↑ Weitekamp MR, Aber RC (1983). "Prolonged bleeding times and bleeding diathesis associated with moxalactam administration". JAMA. 249 (1): 69–71. PMID 6217353.
- ↑ Brown RB, Klar J, Lemeshow S, Teres D, Pastides H, Sands M (1986). "Enhanced bleeding with cefoxitin or moxalactam. Statistical analysis within a defined population of 1493 patients". Arch Intern Med. 146 (11): 2159–64. PMID 3778044.
- Pages with script errors
- CS1 maint: Multiple names: authors list
- Pages with broken file links
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Cephalosporin antibiotics